Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 3
2004 1
2005 6
2006 3
2007 3
2008 4
2009 5
2010 6
2011 3
2012 3
2013 4
2014 10
2015 5
2016 5
2017 5
2018 7
2019 6
2020 4
2021 9
2022 3
2023 5
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

91 results

Results by year

Filters applied: . Clear all
Page 1
Editorial: History in anatomy education.
Duparc F, Grignon B, Kachlik D. Duparc F, et al. Surg Radiol Anat. 2019 Oct;41(10):1101-1102. doi: 10.1007/s00276-019-02335-3. Surg Radiol Anat. 2019. PMID: 31531709 No abstract available.
Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials.
André F, Su F, Solovieff N, Hortobagyi G, Chia S, Neven P, Bardia A, Tripathy D, Lu YS, Lteif A, Taran T, Babbar N, Slamon D, Arteaga CL. André F, et al. Ann Oncol. 2023 Nov;34(11):1003-1014. doi: 10.1016/j.annonc.2023.08.011. Epub 2023 Sep 5. Ann Oncol. 2023. PMID: 37673211 Free article.
BACKGROUND: The phase III MONALEESA trials tested the efficacy and safety of the cyclin-dependent kinase (CDK)4/6 inhibitor ribociclib with different endocrine therapy partners as first- or second-line treatment of hormone receptor-positive/human epidermal growth factor re …
BACKGROUND: The phase III MONALEESA trials tested the efficacy and safety of the cyclin-dependent kinase (CDK)4/6 inhibitor ribociclib with …
Second-line treatment for advanced non-small cell lung cancer: a systematic review.
Barlési F, Jacot W, Astoul P, Pujol JL. Barlési F, et al. Lung Cancer. 2006 Feb;51(2):159-72. doi: 10.1016/j.lungcan.2005.08.017. Epub 2005 Dec 19. Lung Cancer. 2006. PMID: 16360238 Review.
MATERIALS AND METHODS: A systematic review was carried out from 1996 to February 2005. RESULTS: Second-line chemotherapy provides pre-treated NSCLC patients with a clear survival advantage. ...CONCLUSION: Second-line chemotherapy offers NSCLC patients a small but si …
MATERIALS AND METHODS: A systematic review was carried out from 1996 to February 2005. RESULTS: Second-line chemotherapy provides pre …
First-line second generation tyrosine kinase inhibitors in patients with newly diagnosed accelerated phase chronic myeloid leukemia.
Balsat M, Alcazer V, Etienne G, Huguet F, Berger M, Cayssials E, Charbonnier A, Escoffre-Barbe M, Johnson-Ansah H, Legros L, Roy L, Delmer A, Ianotto JC, Orvain C, Larosa F, Meunier M, Amé S, Andreoli A, Cony-Makhoul P, Morisset S, Tigaud I, Rea D, Nicolini FE. Balsat M, et al. Leuk Res. 2023 Jul;130:107308. doi: 10.1016/j.leukres.2023.107308. Epub 2023 May 9. Leuk Res. 2023. PMID: 37230027
Accelerated phase (AP) CML at onset and have poorer prognosis than CP-CML. We hypothesize that off-license use of second generation TKI (TKI2) as front-line therapy might counterbalance this poor prognosis, with limited toxicity. ...
Accelerated phase (AP) CML at onset and have poorer prognosis than CP-CML. We hypothesize that off-license use of second generation T …
Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT).
Barlesi F, Mazieres J, Merlio JP, Debieuvre D, Mosser J, Lena H, Ouafik L, Besse B, Rouquette I, Westeel V, Escande F, Monnet I, Lemoine A, Veillon R, Blons H, Audigier-Valette C, Bringuier PP, Lamy R, Beau-Faller M, Pujol JL, Sabourin JC, Penault-Llorca F, Denis MG, Lantuejoul S, Morin F, Tran Q, Missy P, Langlais A, Milleron B, Cadranel J, Soria JC, Zalcman G; Biomarkers France contributors. Barlesi F, et al. Lancet. 2016 Apr 2;387(10026):1415-1426. doi: 10.1016/S0140-6736(16)00004-0. Epub 2016 Jan 15. Lancet. 2016. PMID: 26777916 Free article.
The presence of a genetic alteration affected first-line treatment for 4176 (51%) of 8147 patients and was associated with a significant improvement in the proportion of patients achieving an overall response in first-line treatment (37% [95% CI 34.7-38.2] for presence of a genet …
The presence of a genetic alteration affected first-line treatment for 4176 (51%) of 8147 patients and was associated with a significant imp …
The obesity treatment dilemma: Why dieting is both the answer and the problem? A mechanistic overview.
Monnier L, Schlienger JL, Colette C, Bonnet F. Monnier L, et al. Diabetes Metab. 2021 May;47(3):101192. doi: 10.1016/j.diabet.2020.09.002. Epub 2020 Sep 28. Diabetes Metab. 2021. PMID: 33002604 Review.
Loosely adherence to recommendations is one of the main causes for the limited efficacy of dieting, but many additional factors can be involved in the hurdles to weight loss. According to the second law of thermodynamics any restriction in dietary energy intake results in …
Loosely adherence to recommendations is one of the main causes for the limited efficacy of dieting, but many additional factors can be invol …
[Recurrent Miller-Fisher syndrome].
Battaglia F, Attane F, Robinson A, Martini L, Siboni J, Tannier C. Battaglia F, et al. Rev Neurol (Paris). 2005 Sep;161(8-9):844-7. doi: 10.1016/s0035-3787(05)85146-x. Rev Neurol (Paris). 2005. PMID: 16244569 French.
Clinically, the first episode was a "classical" MFS, and the second an extensive MFS with tetraparesis and respiratory failure. ...
Clinically, the first episode was a "classical" MFS, and the second an extensive MFS with tetraparesis and respiratory failure. ...
Bruck syndrome: second antenatal diagnosis.
Cuillier F, Alessandri JL, Lemaire P, Fritel X, Harper L. Cuillier F, et al. Fetal Diagn Ther. 2007;22(1):23-8. doi: 10.1159/000095838. Epub 2006 Sep 21. Fetal Diagn Ther. 2007. PMID: 17003551
We describe a French girl who was born with ankle and wrist contractures (second antenatal discovery)....
We describe a French girl who was born with ankle and wrist contractures (second antenatal discovery)....
Computer-Aided Detection and diagnosis for prostate cancer based on mono and multi-parametric MRI: a review.
Lemaître G, Martí R, Freixenet J, Vilanova JC, Walker PM, Meriaudeau F. Lemaître G, et al. Comput Biol Med. 2015 May;60:8-31. doi: 10.1016/j.compbiomed.2015.02.009. Epub 2015 Feb 20. Comput Biol Med. 2015. PMID: 25747341 Review.
Prostate cancer is the second most diagnosed cancer of men all over the world. In the last few decades, new imaging techniques based on Magnetic Resonance Imaging (MRI) have been developed to improve diagnosis. ...
Prostate cancer is the second most diagnosed cancer of men all over the world. In the last few decades, new imaging techniques based …
Semi-preparative high-resolution recycling liquid chromatography.
Gritti F, Basile M, Cormier S, Fogwill M, Gilar M, McDonald T, Riley F, Yan Q. Gritti F, et al. J Chromatogr A. 2018 Sep 7;1566:64-78. doi: 10.1016/j.chroma.2018.06.055. Epub 2018 Jun 23. J Chromatogr A. 2018. PMID: 29958681
Finally, the process is fully automated by programming the time events related to (1) sample cleaning, (2) transfer of the targeted impurity from one to the second twin column, and (3) impurity collection. The process was tested without interruption during one week for the …
Finally, the process is fully automated by programming the time events related to (1) sample cleaning, (2) transfer of the targeted impurity …
91 results